Good morning :)
Neuland Laboratories Ltd

Neuland Laboratories Ltd

NEULANDLAB Share Price

NSE
11,995.000.88% (-106.00)
High
Low
Returns
1D
1W
1M
1Y
5Y
Max
SIP
Loading...
1D
1W
1M
1Y
5Y
Max
SIP

With a market cap of ₹15,525 cr, stock is ranked 389

Stock is 3.59x as volatile as Nifty

NEULANDLAB Stock Scorecard

Performance

Avg

Price return has been average, nothing exciting

Valuation

High

Seems to be overvalued vs the market average

Growth

Avg

Financials growth has been moderate for a few years

Profitability

High

Showing good signs of profitability & efficiency

Entry point

Good

The stock is underpriced and is not in the overbought zone

Red flags

Low

No red flag found

How to use scorecard? Learn more

With a market cap of ₹15,525 cr, stock is ranked 389

Stock is 3.59x as volatile as Nifty

NEULANDLAB Performance & Key Metrics

NEULANDLAB Performance & Key Metrics

No LabelNo LabelPB RatioPB RatioDividend YieldDiv. Yield
86.6710.180.10%
Sector PESector PESector PBSector PBSector Div YldSctr Div Yld
35.105.540.61%

NEULANDLAB Analyst Ratings & Forecast

Detailed Forecast Detailed Forecast 
100%
Analysts have suggested that investors can buy this stock

from 4 analysts

Price Upside

Earnings Growth

Rev. Growth

See Detailed Forecast

NEULANDLAB Company Profile

Neuland Laboratories Limited is engaged in manufacturing active pharmaceutical ingredient (API). The Company also provides custom manufacturing solutions (CMS) to develop and manufacture pharmaceutical ingredients and intermediates.

Investor Presentation

View older View older 

Feb 9, 2026

PDF
View Older Presentations

NEULANDLAB Similar Stocks (Peers)

Compare with peers Compare with peers 

NEULANDLAB Similar Stocks (Peers)

Compare with peers Compare with peers 
PE Ratio
38.30
38.30
1Y Return
1.53%
1.53%
Buy Reco %
94.12
94.12
PE Ratio
74.57
74.57
1Y Return
32.17%
32.17%
Buy Reco %
81.48
81.48
PE Ratio
18.76
18.76
1Y Return
9.41%
9.41%
Buy Reco %
51.61
51.61
PE Ratio
31.36
31.36
1Y Return
11.35%
11.35%
Buy Reco %
72.22
72.22
PE Ratio
18.99
18.99
1Y Return
16.91%
16.91%
Buy Reco %
54.84
54.84
Compare with Peers

NEULANDLAB Sentiment Analysis

NEULANDLAB Sentiment Analysis

New
Crisp summary & key insights to decode earnings calls instantly

NEULANDLAB Stock Summary · February 2026

Neuland Laboratories reported a robust 11.4% year-over-year increase in total income, driven by its commercial Contract Manufacturing Services, despite facing challenges such as a decline in gross margins and heightened working capital issues. The company is strategically transitioning from low-margin API manufacturing to human health-oriented CDMO services, which necessitates significant investments and a longer-term performance outlook. While high inventory levels raise concerns about efficiency, management remains optimistic about future growth, particularly in peptide manufacturing, where increased interest from innovators is evident. The focus on quality project engagement and a commitment to optimizing cash flow are central to navigating current operational complexities and ensuring sustainable growth in the coming years.

NEULANDLAB Stock Growth Drivers
NEULANDLAB Stock Growth Drivers
8
  • Strategic Growth Initiatives

    Neuland Laboratories has made significant investments in capital expenditures, amounting to INR 254 crores in

  • Positive Financial Performance and Operational Efficiency

    Despite a cash outflow, Neuland managed to limit free cash flows to a negative INR

NEULANDLAB Stock Challenges
NEULANDLAB Stock Challenges
6
  • Decline in Gross Margins

    The company reported a decrease in gross margins, with Q3 FY26 gross margin at 52.1%,

  • Deterioration in Working Capital

    The company has experienced a deterioration in working capital, characterized by higher inventories and increased

NEULANDLAB Forecast

NEULANDLAB Forecasts

Price

Revenue

Earnings

NEULANDLAB

NEULANDLAB

Income

Balance Sheet

Cash Flow

NEULANDLAB Income Statement

NEULANDLAB Income Statement

Loading...

Quartersep 2023dec 2023mar 2024jun 2024sep 2024dec 2024mar 2025jun 2025sep 2025dec 2025
Total Revenue420.80394.93390.37465.03315.18457.72335.82300.61516.07447.76
Operating & Other expensessubtract280.26271.56278.09316.24248.62311.43277.29258.26358.73362.58
Depreciation/Amortizationsubtract14.5115.1416.4616.2816.0716.3016.8920.1922.5423.92
Interest & Other Itemssubtract4.433.743.612.671.062.222.354.585.376.79
Taxes & Other Itemssubtract32.3423.0924.6431.9716.5826.1811.493.6732.5813.90
EPS69.5663.4452.6676.2825.6079.1821.6710.8375.4931.62

NEULANDLAB Company Updates

Annual Report and Investor Presentation updates mentioned here are as reported by the company to the exchange
FY 2026FY 2026

Annual Report Pending

Investor Presentation

Feb 9PDF
Nov 7PDF
Jul 31PDF
FY 2025FY 2025

Annual report

PDF

Investor Presentation

May 15PDF
Feb 10PDF
Nov 6PDF
FY 2024FY 2024

Annual report

PDF

Investor Presentation

Aug 3PDF
FY 2023FY 2023

Annual report

PDF

Investor Presentation

May 11PDF
Feb 13PDF
FY 2022FY 2022

Annual report

PDF

Investor Presentation

May 10PDF
FY 2021FY 2021

Annual report

PDF
FY 2020FY 2020

Annual report

PDF
FY 2019FY 2019

Annual report

PDF
FY 2018FY 2018

Annual report

PDF
FY 2017FY 2017

Annual report

PDF
 

NEULANDLAB Stock Peers

NEULANDLAB Past Performance & Peer Comparison

NEULANDLAB Past Performance & Peer Comparison

Comparing 3 stocks from 
Health CarePharmaceuticals

Loading...

StockPE RatioPE RatioPB RatioPB RatioDiv. YieldDividend Yield
Neuland Laboratories Ltd59.6910.180.10%
Sun Pharmaceutical Industries Ltd38.305.770.92%
Torrent Pharmaceuticals Ltd74.5718.770.76%
Dr Reddy's Laboratories Ltd18.763.130.63%

NEULANDLAB Stock Price Comparison

Compare NEULANDLAB with any stock or ETF
Compare NEULANDLAB with any stock or ETF
NEULANDLAB
Loading...

NEULANDLAB Holdings

NEULANDLAB Shareholdings

NEULANDLAB Promoter Holdings Trend

NEULANDLAB Promoter Holdings Trend

Total Promoter Holding
Increasing promoter holding is considered good and reflects management’s positive view about the future outlook

In last 6 months, promoter holding in the company has almost stayed constant

Low Pledged Promoter Holding
Lower pledged promoter holdings is considered better

Pledged promoter holdings is insignificant

NEULANDLAB Institutional Holdings Trend

NEULANDLAB Institutional Holdings Trend

Total Retail Holding
Increasing retail holding can be considered bad as it can reflect that institutions and promoters are selling their stake which is being absorbed by retail investors.

In last 3 months, retail holding in the company has almost stayed constant

Foreign Institutional Holding
Foreign Institutional Holding is quantum of stock held by foreign large-quantities-trading entities. Increasing value indicates growing support and comfort for the stock

In last 3 months, foreign institutional holding of the company has almost stayed constant

Tickertape Separator

NEULANDLAB Shareholding Pattern

NEULANDLAB Shareholding Pattern

Retail and OthersForeign InstitutionsOther Domestic InstitutionsMutual FundsTotal Promoter Holding32.63%10.39%4.32%20.90%31.76%

Mar 2025

Jun 2025

Sep 2025

Dec 2025

NEULANDLAB Shareholding History

NEULANDLAB Shareholding History

SepDec '24MarJunSepDec '2526.46%23.86%22.11%21.69%20.60%20.90%

Mutual Funds Invested in NEULANDLAB

Mutual Funds Invested in NEULANDLAB

No mutual funds holding trends are available

Top 5 Mutual Funds holding Neuland Laboratories Ltd




Funds (Top 5)Market-cap heldWeight3M holding changePortfolio rank
(3M change)
2.1133%1.67%-0.67%50/89 (-5)
1.3359%1.35%-0.38%66/117 (-6)
0.8335%2.07%-0.47%15/91 (-1)

Compare 3-month MF holding change on Screener

NEULANDLAB Insider Trades & Bulk Stock Deals

NEULANDLAB Insider Trades & Bulk Stock Deals

Hmm, looks like there hasn't been any net deal activity in the last 6 months

smallcases containing NEULANDLAB stock

smallcases containing NEULANDLAB stock

Looks like this stock is not in any smallcase yet.

NEULANDLAB Events

NEULANDLAB Events

NEULANDLAB Dividend Trend

No Dividend Cuts
Dividends are the portion of earnings that a company distributes to all its shareholders every year

NEULANDLAB has increased or maintained dividend levels over the last 5 years

Dividend Yield
Dividend return is one of the most important things to be considered while investing for long term. It is the additional return on top of what investors earn through price appreciation

Current dividend yield is 0.10%. An investment of ₹1,000 in the stock is expected to generate dividend of ₹0.99 every year

Dividends

Corp. Actions

Announcements

Legal Orders

NEULANDLAB Dividend Trend

No Dividend Cuts
Dividends are the portion of earnings that a company distributes to all its shareholders every year

NEULANDLAB has increased or maintained dividend levels over the last 5 years

Dividend Yield
Dividend return is one of the most important things to be considered while investing for long term. It is the additional return on top of what investors earn through price appreciation

Current dividend yield is 0.10%. An investment of ₹1,000 in the stock is expected to generate dividend of ₹0.99 every year

NEULANDLAB Upcoming Dividends

NEULANDLAB Upcoming Dividends

No upcoming dividends are available

NEULANDLAB Past Dividends

NEULANDLAB Past Dividends

Cash Dividend

Ex DateEx DateJul 18, 2025

Final
Final | Div/Share: ₹12.00

Dividend/Share

12.00

Ex DateEx Date

Jul 18, 2025

Cash Dividend

Ex DateEx DateJul 12, 2024

Final
Final | Div/Share: ₹14.00

Dividend/Share

14.00

Ex DateEx Date

Jul 12, 2024

Cash Dividend

Ex DateEx DateJul 11, 2023

Final
Final | Div/Share: ₹10.00

Dividend/Share

10.00

Ex DateEx Date

Jul 11, 2023

Cash Dividend

Ex DateEx DateJul 14, 2022

Final
Final | Div/Share: ₹5.00

Dividend/Share

5.00

Ex DateEx Date

Jul 14, 2022

Cash Dividend

Ex DateEx DateJun 29, 2021

Final
Final | Div/Share: ₹3.00

Dividend/Share

3.00

Ex DateEx Date

Jun 29, 2021

NEULANDLAB Stock News & Opinions

NEULANDLAB Stock News & Opinions

Earnings
Neuland Laboratories consolidated net profit declines 60.06% in the December 2025 quarter

Net profit of Neuland Laboratories declined 60.06% to Rs 40.57 crore in the quarter ended December 2025 as against Rs 101.59 crore during the previous quarter ended December 2024. Sales rose 10.47% to Rs 439.71 crore in the quarter ended December 2025 as against Rs 398.03 crore during the previous quarter ended December 2024. ParticularsQuarter EndedDec. 2025Dec. 2024% Var. Sales439.71398.03 10 OPM %17.5421.76 - PBDT78.4088.29 -11 PBT54.4871.98 -24 NP40.57101.59 -60 Powered by Capital Market - Live

1 month agoCapital Market - Live
Corporate
Neuland Laboratories to conduct board meeting

Neuland Laboratories will hold a meeting of the Board of Directors of the Company on 9 February 2026.Powered by Capital Market - Live

1 month agoCapital Market - Live
Spotlight
Neuland Labs rises after Q2 PAT spurts 195% YoY to Rs 97 cr

On a quarter-on-quarter (QoQ) basis, the company's net profit zoomed 596.76%, while revenue rose 75.67% in Q2 FY26. Profit before tax (PBT) soared 161.92% YoY and 636.71% QoQ to Rs 636.71 crore in Q2 FY26. During the quarter, EBITDA stood at Rs 156.9 crore, registering growth of 138.80% compared with Rs 65.7 crore posted in the same quarter last year. EBITDA margin improved 960 bps to 30.40% in Q2 FY26 as against 20.80% in Q2 FY25. Total expenses jumped 45.59% to Rs 386.64 crore in Q2 FY26, compared with Rs 265.75 crore in Q2 FY25. The cost of material consumed stood at Rs 227.64 crore (up 70.94% YoY), employee benefit expenses were at Rs 80.37 crore (up 28.43% YoY), finance cost stood at Rs 5.17 crore (up 387.74% YoY), while manufacturing expenses stood at Rs 45.96 crore (up 8.68% YoY) during the period under review. Sucheth Davuluri, vice-chairman and chief executive officer of the company, said, 'The record high revenue this quarter driven by CMS commercial projects led to the operating leverage reflected in the EBITDA margins, and we expect this momentum to continue through the rest of the year. Given the investments we are making, Neuland is well positioned to take advantage of the number of growth opportunities available to us in both the CDMO and the generic APIs space. Customer interest in Neuland's capabilities continues to be on the rise as we see increased engagement with a diverse range of customers. Our reputation and track record as an agile partner is enabling not just new business but also a greater share of business from existing customers. Our investments are going according to plan and helping to further differentiate Neuland as a partner of choice.' Neuland Laboratories is a pharmaceutical manufacturer providing active pharmaceutical ingredients (APIs), complex intermediates, and custom manufacturing solutions to customers in approximately 80 countries.Powered by Capital Market - Live

4 months agoCapital Market - Live
Earnings
Neuland Laboratories consolidated net profit rises 194.91% in the September 2025 quarter

Net profit of Neuland Laboratories rose 194.91% to Rs 96.85 crore in the quarter ended September 2025 as against Rs 32.84 crore during the previous quarter ended September 2024. Sales rose 65.45% to Rs 514.27 crore in the quarter ended September 2025 as against Rs 310.84 crore during the previous quarter ended September 2024. ParticularsQuarter EndedSep. 2025Sep. 2024% Var. Sales514.27310.84 65 OPM %30.2520.02 - PBDT151.9865.50 132 PBT129.4449.42 162 NP96.8532.84 195 Powered by Capital Market - Live

4 months agoCapital Market - Live
Spotlight
Volumes spurt at Neuland Laboratories Ltd counter

India Cements Ltd, Five-Star Business Finance Ltd, Sagility Ltd, Endurance Technologies Ltd are among the other stocks to see a surge in volumes on BSE today, 30 October 2025.Neuland Laboratories Ltd registered volume of 20530 shares by 10:47 IST on BSE, a 16.61 fold spurt over two-week average daily volume of 1236 shares. The stock rose 2.40% to Rs.15,743.55. Volumes stood at 1163 shares in the last session.India Cements Ltd registered volume of 88566 shares by 10:47 IST on BSE, a 9.86 fold spurt over two-week average daily volume of 8985 shares. The stock rose 5.10% to Rs.411.00. Volumes stood at 13842 shares in the last session.Five-Star Business Finance Ltd notched up volume of 20.84 lakh shares by 10:47 IST on BSE, a 9.85 fold spurt over two-week average daily volume of 2.12 lakh shares. The stock rose 8.14% to Rs.652.50. Volumes stood at 14.42 lakh shares in the last session.Sagility Ltd registered volume of 223.05 lakh shares by 10:47 IST on BSE, a 8.89 fold spurt over two-week average daily volume of 25.10 lakh shares. The stock rose 9.96% to Rs.55.98. Volumes stood at 57.99 lakh shares in the last session.Endurance Technologies Ltd notched up volume of 31455 shares by 10:47 IST on BSE, a 6.32 fold spurt over two-week average daily volume of 4978 shares. The stock rose 0.21% to Rs.2,850.90. Volumes stood at 13535 shares in the last session.Powered by Capital Market - Live

4 months agoCapital Market - Live
Corporate
Neuland Laboratories schedules board meeting

Neuland Laboratories will hold a meeting of the Board of Directors of the Company on 7 November 2025.Powered by Capital Market - Live

4 months agoCapital Market - Live
Earnings
Neuland Laboratories consolidated net profit declines 85.80% in the June 2025 quarter

Net profit of Neuland Laboratories declined 85.80% to Rs 13.90 crore in the quarter ended June 2025 as against Rs 97.87 crore during the previous quarter ended June 2024. Sales declined 33.41% to Rs 292.75 crore in the quarter ended June 2025 as against Rs 439.60 crore during the previous quarter ended June 2024. ParticularsQuarter EndedJun. 2025Jun. 2024% Var. Sales292.75439.60 -33 OPM %11.7828.06 - PBDT37.76125.49 -70 PBT17.57109.21 -84 NP13.9097.87 -86 Powered by Capital Market - Live

7 months agoCapital Market - Live
Corporate
Neuland Laboratories to hold board meeting

Neuland Laboratories will hold a meeting of the Board of Directors of the Company on 31 July 2025.Powered by Capital Market - Live

8 months agoCapital Market - Live
Spotlight
Volumes soar at Neuland Laboratories Ltd counter

Ola Electric Mobility Ltd, Anand Rathi Wealth Ltd, Castrol India Ltd, Piramal Enterprises Ltd are among the other stocks to see a surge in volumes on NSE today, 14 July 2025.Neuland Laboratories Ltd clocked volume of 8.19 lakh shares by 14:14 IST on NSE, a 13.83 times surge over two-week average daily volume of 59191 shares. The stock gained 13.57% to Rs.13,970.00. Volumes stood at 74664 shares in the last session.Ola Electric Mobility Ltd witnessed volume of 4281.51 lakh shares by 14:14 IST on NSE, a 11.24 times surge over two-week average daily volume of 381.06 lakh shares. The stock increased 13.69% to Rs.45.25. Volumes stood at 286.32 lakh shares in the last session.Anand Rathi Wealth Ltd saw volume of 21.36 lakh shares by 14:14 IST on NSE, a 8.02 fold spurt over two-week average daily volume of 2.66 lakh shares. The stock increased 8.27% to Rs.2,394.70. Volumes stood at 17.1 lakh shares in the last session.Castrol India Ltd notched up volume of 225.99 lakh shares by 14:14 IST on NSE, a 7.74 fold spurt over two-week average daily volume of 29.18 lakh shares. The stock rose 1.91% to Rs.224.10. Volumes stood at 13.1 lakh shares in the last session.Piramal Enterprises Ltd witnessed volume of 40.33 lakh shares by 14:14 IST on NSE, a 6.27 times surge over two-week average daily volume of 6.44 lakh shares. The stock increased 5.10% to Rs.1,279.60. Volumes stood at 25.09 lakh shares in the last session.Powered by Capital Market - Live

8 months agoCapital Market - Live
Spotlight
Neuland Laboratories Ltd leads gainers in 'A' group

Anand Rathi Wealth Ltd, Piramal Enterprises Ltd, Vodafone Idea Ltd and Tega Industries Ltd are among the other gainers in the BSE's 'A' group today, 14 July 2025.Neuland Laboratories Ltd spiked 10.08% to Rs 13546.9 at 11:46 IST. The stock was the biggest gainer in the BSE's 'A' group. On the BSE, 56484 shares were traded on the counter so far as against the average daily volumes of 2317 shares in the past one month. Anand Rathi Wealth Ltd soared 8.18% to Rs 2392.4. The stock was the second biggest gainer in 'A' group. On the BSE, 34271 shares were traded on the counter so far as against the average daily volumes of 21553 shares in the past one month. Piramal Enterprises Ltd surged 6.18% to Rs 1291.75. The stock was the third biggest gainer in 'A' group. On the BSE, 1.21 lakh shares were traded on the counter so far as against the average daily volumes of 14320 shares in the past one month. Vodafone Idea Ltd advanced 5.87% to Rs 7.58. The stock was the fourth biggest gainer in 'A' group. On the BSE, 411.08 lakh shares were traded on the counter so far as against the average daily volumes of 593.47 lakh shares in the past one month. Tega Industries Ltd gained 5.80% to Rs 1785.05. The stock was the fifth biggest gainer in 'A' group. On the BSE, 9399 shares were traded on the counter so far as against the average daily volumes of 4569 shares in the past one month. Powered by Capital Market - Live

8 months agoCapital Market - Live

Frequently asked questions

Frequently asked questions

  1. What is the share price of Neuland Laboratories Ltd (NEULANDLAB) today?

    The share price of NEULANDLAB as on 20th March 2026 is ₹11995. The stock prices are volatile and keep changing through the day depending upon various factors and market conditions.

  2. What is the return on Neuland Laboratories Ltd (NEULANDLAB) share?

    The past returns of Neuland Laboratories Ltd (NEULANDLAB) share are
    • Past 1 week: -3.27%
    • Past 1 month: -8.19%
    • Past 3 months: -25.24%
    • Past 6 months: -21.63%
    • Past 1 year: 2.68%
    • Past 3 years: 637.93%
    • Past 5 years: 509.58%

  3. What are the peers or stocks similar to Neuland Laboratories Ltd (NEULANDLAB)?
  4. What is the dividend yield % of Neuland Laboratories Ltd (NEULANDLAB) share?

    The current dividend yield of Neuland Laboratories Ltd (NEULANDLAB) is 0.10.

  5. What is the market cap of Neuland Laboratories Ltd (NEULANDLAB) share?

    Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Neuland Laboratories Ltd (NEULANDLAB) is ₹15525.45 Cr as of 20th March 2026.

  6. What is the 52 week high and low of Neuland Laboratories Ltd (NEULANDLAB) share?

    The 52-week high of Neuland Laboratories Ltd (NEULANDLAB) is ₹19747 and the 52-week low is ₹10400.15.

  7. What is the PE and PB ratio of Neuland Laboratories Ltd (NEULANDLAB) stock?

    The P/E (price-to-earnings) ratio of Neuland Laboratories Ltd (NEULANDLAB) is 59.69. The P/B (price-to-book) ratio is 10.18.

  8. Which sector does Neuland Laboratories Ltd (NEULANDLAB) belong to?

    Neuland Laboratories Ltd (NEULANDLAB) belongs to the Health Care sector & Pharmaceuticals sub-sector.

  9. How to buy Neuland Laboratories Ltd (NEULANDLAB) shares?

    You can directly buy Neuland Laboratories Ltd (NEULANDLAB) shares on Tickertape. Simply sign up, connect your demat account and place your order.